NCT05194397: IAMFIT

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

Recruiting now Phase 2 Last updated 4 December 2025

What this trial tests

Phase 2 trial testing Nicotinamide Riboside in Lymphoblastic Leukemia in 80 participants. Currently enrolling.

Timeline

23 February 2023

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	Children's Hospital of Philadelphia
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	quadruple
Primary purpose	treatment
Enrollment	80
Start date	23 February 2023
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	3 locations across United States

Drugs / interventions tested

• Nicotinamide Riboside — full drug profile →
• Placebo
• Exercise Intervention

Conditions studied

• Lymphoblastic Leukemia — all drugs for Lymphoblastic Leukemia →
• Cancer Survivors — all drugs for Cancer Survivors →
• Aplastic Anemia — all drugs for Aplastic Anemia →
• Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →

Sponsor

Children's Hospital of Philadelphia

Who can join

Adults 10 to 30, any sex, with Lymphoblastic Leukemia or Cancer Survivors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors.

The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity muscle mass from baseline to 16 weeks, the change in muscle OXPHOS capacity from baseline to 16 weeks, and the change in aerobic capacity (VO2 max) from baseline to 16 weeks.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer: <i>JACC: CardioOncology</i> State-of-the-Art Review.
   Hammoud RA, Mulrooney DA, Rhea IB, Yu C, et al · · 2024 · cited 19× · PMID 38510292 · DOI 10.1016/j.jaccao.2023.12.008
2. Exercise training and NR supplementation to improve muscle mass and fitness in adolescent and young adult hematopoietic cell transplant survivors: a randomized controlled trial {1}.
   Song M, Armenian SH, Bhandari R, Lee K, et al · · 2022 · cited 15× · PMID 35854224 · DOI 10.1186/s12885-022-09845-1
3. The advent of precision nutrigeroscience in cancer: from clinic towards molecular biology.
   Gao Z, Liu Y, Cui Y, Han Y, et al · · 2026 · cited 2× · PMID 40850675 · DOI 10.1016/j.jare.2025.08.034